A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Abstract Forty‐six patients with primary biliary cirrhosis from a single centre were studied in a randomized placebo‐controlled trial to determine the effectiveness of ursodeoxycholic acid (UDCA) over a 2 year period. The two groups were well‐matched at baseline. For each parameter, by calculating the difference between the median changes with time between the UDCA group and the placebo group, it was found that from entry, with respect to placebo, there were differences between median changes (MCD) favouring the UDCA group in bilirubin {MCD 5 μmol/L [95% confidence interval (CI) 1 to 12] at 1 year and 5 μmol/L (95% CI 1 to 9) at 2 years}, alkaline phosphatase MCD 242 iu/L (95% CI 107 to 360) at 1 year and 268 iu/L (95% CI 146 to 424) at 2 years and aspartate aminotransferase MCD 26 iu/L (95% CI 12 to 41) at 1 year and 37 iu/L (95% CI 16 to 64) at 2 years. Within the UDCA group, there was long‐term fall in alkaline phosphatase [median fall 116 iu/L (95% CI 93 to 378) at 2 years and aspartate aminotransferase [median fall 18 iu/L (95% CI 6 to 47) at 2 years; however, the major change in bilirubin was a modest rise over 2 years in the placebo group [median rise 2 μmol/L (95% CI 1 to 9)]. Changes in albumin, prothrombin ratio and immunoglobulins were generally minor and not significant. Ursodeoxycholic acid did not generally influence stage progression or histological features, although a smaller percentage of non‐cirrhotic patients were documented as having developed cirrhosis on UDCA compared to placebo (14 vs 57%) over the 2 years. There appeared to be no consistent effect on pruritus and general well‐being. The medication was well‐tolerated and safe. In conclusion, UDCA appears to have beneficial effects on some serum biochemical markers in primary biliary cirrhosis and so may have a role in retarding disease progression. It could be useful in combination with an immunosuppressive or an anti‐fibrotic agent.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prognosis in primary biliary cirrhosis: Model for decision making
Dickson, R. E., Grambsch, P. M., Fleming, T. R., Fisher, L. D., & Langworthy, A. (1989) · Hepatology · doi:10.1002/hep.1840100102 · Cited by 816
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Treatment of pruritus of primary biliary cirrhosis with rifampin
Podesta, A., Lopez, P., Terg, R., Villamil, F., Flores, D., Mastai, R., Udaondo, C. B., & Companc, J. P. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01300759 · Cited by 267
Treatment of pruritus in primary biliary cirrhosis with rifampin
Ghent, C. N., & Carruthers, S. G. (1988) · Gastroenterology · doi:10.1016/0016-5085(88)90442-8 · Cited by 257
Research works printed but not linked: 45
- 10.1016/0016-5085(89)91698-3 · DOI · Paper page
- 10.1016/S0140-6736(87)91610-2 · DOI · Paper page
- 10.1002/hep.1840100404 · DOI · Paper page
- Matsuzaki Y., 1990, Improvement of biliary enzyme levels and itching as a result of long‐term administration of ursodeoxycholic acid in primary biliary cirrhosis, Am. J. Gastroenterol., 85, 15
- 10.1016/0168-8278(90)90134-D · DOI
- 10.1002/hep.1840120308 · DOI · Paper page
- Fisher M. M., 1986, Influence of ursodeoxycholic acid (UDCA) on biochemical parameters in cholestatic liver disease (Abstr.), Gastroenterology, 90, 1725
- Hadziyannis S. J., 1989, A randomised controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.), Hepatology, 10, 580
- Podda M., 1989, Ursodeoxycholic acid (UDCA) for symptomatic primary biliary cirrhosis (PBC): A double‐blind multicenter trial (Abstr.), Hepatology, 10, 639
- Heathcote E. J. L., 1992, The Canadian multi‐centre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis (Abstr.), Hepatology, 16, 91A
- Lindor K. D. L., 1992, Ursodeoxycholic acid is beneficial therapy for patients with primary biliary cirrhosis (Abstr.), Hepatology, 16, 91A
- Hayashi H., 1988, Ursodeoxycholic acid (UDCA) (Abstr.). reduces secondary liver damage in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) (Abstr.), Hepatology, 8, 1417
- Wiesner R. H., 1990, Ursodeoxycholic acid therapy for primary biliary cirrhosis: Progression of disease despite near normalization of biochemical liver tests (Abstr.), Hepatology, 12, 843
- Myszor M., 1990, No symptomatic or histological benefit from ursodeoxycholic acid treatment in PBC after 1 year controlled pilot study (Abstr.), Hepatology, 12, 415
- 10.1136/bmj.297.6662.1501 · DOI · Paper page
- 10.1097/00004836-199004000-00012 · DOI · Paper page
- 10.1002/hep.1840080339 · DOI
- Gardner M. J., 1989, Statistics with Confidence, 140
- 10.1056/NEJM198612043152304 · DOI · Paper page
- 10.1016/S0016-5085(19)33223-8 · DOI · Paper page
- Palmer R. H., 1972, Bile acids, liver injury, and liver disease, Arch. Intern. Med., 130, 606, 10.1001/archinte.1972.03650040130012 · doi:10.1001/archinte.1972.03650040130012 · Paper page
- Dryzka H., 1976, Hepatic toxicity in the Rhesus monkey treated with chenodeoxycholic acid for six months — Biochemical and ultrastructual studies, Gastroenterology, 70, 93, 10.1016/S0016-5085(76)80409-X · DOI
- Yousef I. M., 1981, Lithocholate cholestasis‐sulfated glycolithocholate‐induced intrahepatic cholestasis in rats, Gastroenterology, 80, 233, 10.1016/0016-5085(81)90709-5 · DOI
- 10.1172/JCI111356 · DOI
- 10.1002/hep.1840040416 · DOI · Paper page
- Kitani K., 1985, Tauroursodeoxycholate prevents biliary protein excretion induced by other bile salts in the rat, Am. J. Physiol., 248, G407
- 10.1002/hep.1840120523 · DOI · Paper page
- 10.1016/0168-8278(90)90133-C · DOI
- 10.1016/0016-5085(91)90602-H · DOI · Paper page
- Greim H., 1972, Mechanisms of cholestasis. 6. Bile acids in human livers with or without biliary obstruction, Gastroenterology, 63, 846
- 10.1016/0016-5085(78)90068-9 · DOI
- 10.1016/S0016-5085(83)80004-3 · DOI
- 10.1007/BF01317087 · doi:10.1007/bf01317087
- 10.1002/hep.1840120307 · DOI · Paper page
- Hadziyannis S. J., 1991, Bile Acids as Therapeutic Agents, 287
- 10.1016/0016-5085(90)90834-N · DOI
- 10.1002/hep.1840120521 · DOI · Paper page
- Güldütuna S., 1990, Ursodeoxycholic acid protects basolateral liver plasma membranes against toxic bile acid salts (Abstr.), Hepatology, 12, 997
- 10.1002/hep.1840140527 · DOI · Paper page
- Thielmann L., 1991, Bile Acids as Therapeutic Agents, 243
- 10.1002/hep.1840110104 · DOI · Paper page
- 10.1002/hep.1840160213 · DOI · Paper page
- 10.1002/hep.1840160213 · DOI · Paper page
- 10.1002/hep.1840160317 · DOI
- 10.1016/0016-5085(93)90440-N · DOI
Cited by
Hirschfield, G. M., Beuers, U., Corpechot, C., Invernizzi, P., Jones, D., Marzioni, M., & Schramm, C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.03.022 · Cited by 1,480
Hirschfield, G. M., Dyson, J. K., Alexander, G. J. M., Chapman, M. H., Collier, J., Hübscher, S., Patanwala, I., Pereira, S. P., Thain, C., Thorburn, D., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315259 · Cited by 362
Goulis, J., Leandro, G., & Burroughs, A. K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11293-x · Cited by 315
Ursodeoxycholic acid for primary biliary cirrhosis
Rudic, J. S., Poropat, G., Krstic, M. N., Bjelakovic, G., & Gluud, C. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000551.pub3 · Cited by 270
Gong, Y., Huang, Z., Christensen, E., & Gluud, C. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01235.x · Cited by 131
“Two trials evaluated symptoms using visual analog scales, (31, 37) and neither showed any significant difference between the UDCA and placebo group.”
Method
Metadata
- Authors
- TURNER, I. B., MYSZOR, M., MITCHISON, H. C., BENNETT, M. K., BURT, A. D., & JAMES, O. F. W.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 1994-04
- Volume
- 9
- Issue
- 2
- Pages
- 162-168
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W2071178569
- Cited by
- 47
- References
- 4
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. https://app.cochat.ai/papers/10.1111/j.1440-1746.1994.tb01237.x
- The paper
- TURNER, I. B., MYSZOR, M., MITCHISON, H. C., BENNETT, M. K., BURT, A. D., & JAMES, O. F. W. (1994). A two year controlled trial examining the effectiveness of ursodeoxycholic acid in primary biliary cirrhosis. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/j.1440-1746.1994.tb01237.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.